| Document |
Document Title |
|
WO/2024/153225A1 |
The disclosure is directed to novel ALPK1 inhibitors having the Formula (I), or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, a stable isotopic variant, a prodrug, or a crystal form thereof. The disclosure is also directe...
|
|
WO/2024/152512A1 |
A lipid compound for delivery of a therapeutic agent, a preparation method therefor and a use thereof. The lipid compound is a compound having structural formula (I) or a pharmaceutically acceptable form thereof. The lipid compound may b...
|
|
WO/2024/149370A1 |
The present invention provides a compound, a preparation method, and lipid nanoparticles and a pharmaceutical composition thereof. The compound comprises: at least one structural general formula of formula (I-1), or the compound as a pha...
|
|
WO/2024/150068A2 |
The present disclosure provides for compounds of Formula (I): wherein R1 has any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and condit...
|
|
WO/2024/141543A1 |
The invention concerns a compound of formula (I): the process for the preparation thereof and the use thereof as photoinitiator, preferably as photoinitiator activable under 350-460 nm light irradiation, notably to cure formulations comp...
|
|
WO/2024/144009A1 |
The present invention relates to: ionized lipids comprising lipids with a branched structure; a lipid nanoparticle formulation using same; and use thereof. The ionized lipids of the present invention are a biodegradable lipid material wi...
|
|
WO/2024/141105A1 |
Disclosed herein are a lipid compound comprising an isonitrile or a carboxylic acid terminal group, and a preparation method therefor and the use thereof in the preparation of a lipid compound that can be used for gene delivery. Also dis...
|
|
WO/2024/140595A1 |
Disclosed in the present invention are a tricyclic compound, a pharmaceutical composition thereof and the use thereof. Specifically, disclosed in the present invention is a compound as represented by formula (I) or a pharmaceutically acc...
|
|
WO/2024/137981A1 |
Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein Ring A, Ring B, L, RB, Rc, n, and p are as defined herein. Also provided are pharmaceutically acceptable compositions comprising a compound of ...
|
|
WO/2024/134480A1 |
The present invention relates to monomers of formula (I) having a nitrogen atom that can be protonated at relatively low pH values (e.g., less than pH 9.5 or less than pH 9), polymers containing monomeric units derived from these monomer...
|
|
WO/2024/133292A1 |
The invention relates to novel CCR8 antagonists, based on NS-15 as lead structure, were designed and synthesized. To maintain the hydrogen bond potential, focus was on the isosteric replacements of the amide bond. In addition, isosters o...
|
|
WO/2024/131717A1 |
The present invention relates to the field of biological medicines, in particular to cationic lipid compounds capable of being used for nucleic acid delivery, a preparation method therefor and the use thereof. LNPs prepared from the cati...
|
|
WO/2024/136309A1 |
The present invention relates to a novel ionizable lipid compound represented by formula (I) or a salt thereof, and lipid nanoparticles including the same. Lipid nanoparticles including a novel ionizable lipid compound according to the p...
|
|
WO/2024/125469A1 |
Disclosed herein are novel compounds and compositions involving the same, lipid particles including the novel compounds, as well as additional lipids such as phospholipids, structural lipids, and PEG lipids, and the use of the compounds ...
|
|
WO/2024/128525A1 |
The present invention relates to a novel lipid compound and a lipid nanoparticle composition comprising same. More particularly, the lipid nanoparticle composition comprises ionized lipids, helper lipids, PEG-lipids, and additives, and c...
|
|
WO/2024/125649A1 |
Provided are a nucleic acid-loaded lipid nanocarrier, a preparation method therefor, and use thereof. Firstly, provided is a nanocarrier composition for a nucleic acid drug. Based on a total molar weight of lipids in the composition of 1...
|
|
WO/2024/122345A1 |
The present invention addresses the problem of providing a method for producing a homo-coupling reaction product, whereby it becomes possible to substantially eliminate the use of an organic solvent, to carry out a reaction under a mild ...
|
|
WO/2024/112123A1 |
The present invention relates to a compound represented by chemical formula 1 described in the present specification, and a pharmaceutical composition for prevention or treatment of cancer, containing same as an active ingredient. It is ...
|
|
WO/2024/110381A1 |
It is provided an ionizable lipid of formula (I) or a pharmaceutically acceptable salt thereof, or a stereoisomer of any one of them; a lipid nanoparticle comprising the ionizable lipid, particularly, as an encapsulation agent, optionall...
|
|
WO/2024/111511A1 |
Provided are: an actinic ray-sensitive or radiation-sensitive resin composition containing a resin (A) and a salt (B) that is a compound represented by a specific general formula (B-1); an actinic ray-sensitive or radiation-sensitive fil...
|
|
WO/2024/109794A1 |
Provided are cationic lipid compounds represented by formula (I), which can be applied to lipid nanoparticles such that the lipid nanoparticles can target different tissue organs for drug delivery. The cationic lipid compounds or a lipid...
|
|
WO/2024/109929A1 |
Provided in the present invention are an ionizable lipid, and a drug delivery system containing the ionizable lipid. Specifically, provided in the present invention is an ionizable lipid having the structure of formula (I), or a pharmace...
|
|
WO/2024/107308A1 |
Aminoalkyl piperazine (poly) pyrophosphates as effective flame retardants and thermoplastic polymer resins containing such flame retardants. These flame retarded resins are particularly useful in electrical and electronic components, suc...
|
|
WO/2024/104411A1 |
The present application provides a memantine urea derivative, a preparation method therefor, and use thereof, which relate to the technical field of pharmaceutics. The memantine urea derivative provided by the present application has a t...
|
|
WO/2024/107434A1 |
The present invention relates to compounds of formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof. Furthermore, the present invention relates to compounds of formula (I), or a salt, stereoisomer, tautomer or N-oxide thereof,...
|
|
WO/2024/105007A1 |
The present invention relates to compounds of formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof. Furthermore, the present invention relates to compounds of formula (I), or a salt, stereoisomer tautomer or N-oxide thereof, ...
|
|
WO/2023/018990A9 |
New lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells and tissue. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection ...
|
|
WO/2024/094098A1 |
Provided in the present application are a compound for a delivery system and the use thereof, and an ionizable lipid having a hydrogen bond providing group.
|
|
WO/2024/093816A1 |
Disclosed is a method for preparing hexamethylenediamine. The method comprises the following steps: (1) under an ammoniation reaction condition, optionally in the presence of a first solvent, subjecting hexanediol and ammonia to an ammon...
|
|
WO/2024/087251A1 |
A cysteine-residue-specific chemical probe, which has similar reaction capacity and a higher reaction speed in comparison with existing IA chemical probes, and has certain differences in the types of labelled proteins because of a very s...
|
|
WO/2024/092235A2 |
Provided herein are substituted phenylbenzenesulfonamide compounds and compositions thereof for modulating TRPML1. In some embodiments, the compounds and compositions are provided for treatment of neurodegenerative diseases.
|
|
WO/2024/082629A1 |
Provided is a piperazine substituted phenol derivative having a structure as represented by formula (I). The compound has good salt forming properties and excellent water solubility, can meet the requirements of preparations, is low in m...
|
|
WO/2024/084379A1 |
The present invention relates to a novel process for the preparation of amorphous solid dispersion of 1-{3-[3-(4-chlorophenyl) propoxy] propyl} piperidine, hydrochloride with Hydroxypropyl beta-Cyclodextrin (HPβCD) (1) The present inven...
|
|
WO/2024/079351A1 |
The present invention relates to a compound of general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof. The invention further relates to the use of the compounds of the invention as neuroprotective and/or neurore...
|
|
WO/2024/079128A1 |
The invention relates to compounds and their therapeutic use, said compounds having the formula (I): wherein, for example, Z is representing a (II) X is representing a NR5R6 group wherein R5 and R6 are hydrogen, R1 is represe...
|
|
WO/2024/080321A1 |
The present invention provides: a compound which is capable of producing a polymer that has excellent alkali durability; a polymer which comprises this compound as a monomer; an electrolyte membrane which uses this polymer and has excell...
|
|
WO/2024/078387A1 |
A substituted 3-fluorobenzenepropanoate compound represented by formula (I), an optical isomer thereof, a pharmaceutically acceptable salt thereof, a solvate (such as a hydrate) thereof, a clathrate thereof, a racemate thereof, a co-crys...
|
|
WO/2024/077232A2 |
The present disclosure relates, in part, to immune cell targeted lipid nanoparticle (LNP) compositions, and methods of use thereof for ex vivo delivery of nucleic acid molecules and/or therapeutic agents to a target cell. In certain embo...
|
|
WO/2024/074501A1 |
The present invention relates to a process for the fluorination and/or cyclization of an amino alkene or alkyne in a continuous-stream microreactor. The invention also relates to a facility for performing such a process.
|
|
WO/2024/072908A1 |
Provided herein are compounds having one or more cleavable disulfide moieties and one or more hydrophobic tail moieties (HTM) for delivery of one or more therapeutic or diagnostic agents. In some embodiments, the one or more therapeutic ...
|
|
WO/2024/068553A1 |
The present invention relates to tertiary amide compounds of formula (II), or a pharmaceutically acceptable salt thereof, wherein R7 comprises a group X which is -S(=O)2OH, -S(=O)OH or -P(=O)(OH)2- The compounds are capable of solubilizi...
|
|
WO/2024/060641A1 |
The present invention provides a cyclotriarylphosphine ligand represented by general formula (I), and a method for preparing same. The present invention also provides a complex of palladium in coordination with the cyclotriarylphosphine ...
|
|
WO/2024/059745A2 |
A series of novel substituted (hetero)arylmethanamines is described which bind to the N-methyl-D-aspartate receptor. Such compounds have value in various therapeutic indications including, but not limited to, pain, depression, tinnitus, ...
|
|
WO/2024/052923A1 |
One or more ionizable lipid(s) and lipid nanoparticles comprising same are provided. Pharmaceutical compositions comprising the lipid nanoparticles encapsulating an active agent are also provided.
|
|
WO/2024/054669A2 |
The present disclosure provides compounds according to Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, and XIV used as a component of lipid nanoparticle compositions for the delivery of a biological and/or therapeutic age...
|
|
WO/2024/050352A2 |
The present disclosure provides modified immune cells or precursors thereof comprising chimeric antigen receptors and surface-bound, biologically inert molecules. Also included are methods of preparing said modified immune cells and meth...
|
|
WO/2024/049979A2 |
Novel ionizable lipids and lipid nanoparticles that can be used in the delivery of therapeutic cargos are disclosed.
|
|
WO/2024/050062A1 |
The present disclosure is concerned with substituted aminopiperazine compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in the treatment of antimicrobial infections such a...
|
|
WO/2024/043334A1 |
The present invention addresses the problem of providing a compound and pharmaceutical composition that possesses inhibitory activity against the drug efflux pumps of drug-resistant bacteria and, when used in combination with another dru...
|
|
WO/2024/040496A1 |
Disclosed are an antiviral compound, and a preparation method therefor and a use thereof, particularly an anti-coronavirus compound capable of being used as a PLpro inhibitor, and a preparation method therefor and a use thereof. The comp...
|
